Research Reports | Market Assessment
July 2018

Rheumatoid Arthritis | Current Treatment | EU5 | 2018

Five TNF inhibitors, five biologics with alternative mechanisms of action, and two JAK inhibitors are approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy, Spain, and the United Kingdom). The TNF inhibitors are the most widely prescribed biologics in RA patients refractory to conventional DMARDs owing to their efficacy, postmarketing safety data, and physicians’ familiarity with them. However, the high-priced, branded TNF inhibitors face a competitive threat from the launch of biosimilars, including biosimilar infliximab, biosimilar etanercept, and biosimilar rituximab, which provide cost-effective alternatives. In addition, the newlylaunched oral JAK inhibitors are poised to take market share away from biological injections. The Rheumatoid Arthritis Current Treatment (EU5) content provides in-depth analysis of rheumatologists’ treatment and prescribing practices in the crowded RA market, including drivers of treatment selection, obstacles to biologics use, analysis of patient share, and anticipated changes in drug usage.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports